Data from Bayer’s cardiovascular portfolio in heart failure and cardiac amyloidosis will be presented, including ...

A Swiss real-world study of 38 palliative care patients found that rapid intravenous opioid titration reduced median pain scores from 8 to 2 within about eight minutes, with 90 percent of patients ...

Advancements in 2D NMR and automation improve drug discovery, enabling precise analysis of protein binding through chemical ...

TLANDO is approved by Health Canada as a testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism) ...

A nationally representative Swiss survey finds that 2.5 percent of the population has used GLP-1 receptor agonists, mostly ...

Incretin therapies function by mimicking natural intestinal hormones like glucagon-like peptide-1 (GLP-1), which enhance ...

<?xml encoding="utf-8" ?> Health Canada has given the go-ahead to Lipocine Inc. LPCN and its licensing partner, Verity ...

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity ...

Health Canada approved TLANDO for testosterone replacement therapy in adult men with hypogonadism, with Lipocine’s commercial partner Verity Pharma targeting a Canadian launch by the end of 2026. Key ...

Tavapadon, sold under the brand name JUVMO, won FDA approval on September 28, 2026 for adults with Parkinson’s disease, and ...

Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...

Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial. Survodutide (Boehringer Ingelheim), a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor ...